Fulcrum Therapeutics (FULC) Gains from Investment Securities (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Gains from Investment Securities for 7 consecutive years, with -$200000.0 as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities rose 75.4% to -$200000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$913000.0 through Dec 2025, down 1149.43% year-over-year, with the annual reading at $11.6 million for FY2025, 24.49% up from the prior year.
  • Gains from Investment Securities for Q4 2025 was -$200000.0 at Fulcrum Therapeutics, down from $57105.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was $5.0 million in Q3 2021, with the low at -$813000.0 in Q4 2024.
  • Average Gains from Investment Securities over 5 years is $944415.3, with a median of $203437.0 recorded in 2021.
  • The sharpest move saw Gains from Investment Securities soared 7610.03% in 2024, then plummeted 98.0% in 2025.
  • Over 5 years, Gains from Investment Securities stood at $500000.0 in 2021, then tumbled by 80.0% to $100000.0 in 2022, then tumbled by 62.96% to $37045.0 in 2023, then crashed by 2294.63% to -$813000.0 in 2024, then skyrocketed by 75.4% to -$200000.0 in 2025.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at -$200000.0, $57105.0, and $3.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.